Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Summary
An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.
Official title: Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke: An Open-label, Blinded Endpoint, Randomized Controlled Trial
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
472
Start Date
2023-07
Completion Date
2027-07
Last Updated
2023-06-18
Healthy Volunteers
No
Conditions
Interventions
Aspirin
See arm/group descriptions.
Clopidogrel
See arm/group descriptions.
Alteplase
See arm/group descriptions.
Locations (1)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China